Figure 7.

Transmigration activity of the BC cell lines MCF-7, BT-474, and MDA-MB-231 after treatment of cEND and hCMEC/D3 with E2 and DPN in the concentration 10⁻¹⁰ M in comparison to the untreated control (grey (1): differentiation + treatment with solvent only (control); blue (2): differentiation of cancer and endothelial cells with E2 + treatment with solvent only; green (4): differentiation of cancer and endothelial cells with E2 + treatment with DPN). (a) cEND + MCF-7: transmigration of MCF-7 cells in the in vitro model of cEND showed a significant increase after differentiation of cancer and endothelial cells with E2 (2), whereby a subsequent treatment with DPN (4) also led to a significantly increased result; (b) cEND + BT-474: transmigration of BT-474 cells in the cell culture model of cEND did not differ significantly by the treatments; (c) cEND + MDA-MB-231: transmigration of MDA-MB-231 cells over the monolayer of cEND cells was significantly increased by differentiation of cancer and endothelial cells with E2 (2), a result that did not change after the DPN treatment (4); (d) hCMEC/D3 + MCF-7: transmigration of MCF-7 cells in the in vitro model of hCMEC/D3 showed no significant changes; (e) hCMEC/D3 + BT-474: transmigration of BT-474 cells in the cell culture model of hCMEC/D3 did not alter significantly; (f) hCMEC/D3 + MDA-MB-231: transmigration of MDA-MB-231 cells over the monolayer of hCMEC/D3 cells increased significantly by differentiation of cancer and endothelial cells with E2 (2), however, subsequent DPN treatment (4) only led to a slightly less significant increase in transmigration. D: Differentiation media; T: Treatment media; all means ± SD; n = 3; Shapiro–Wilk test (α = 0.05): passed Tukey’s post hoc multiple comparisons test; 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***).